Principal Financial Group
GLUE icon

Principal Financial Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Principal Financial Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
49,001
+6,610
+16% +$125K ﹤0.01% 1921
2026
Q1 		$697K Buy
+42,391
New +$811K ﹤0.01% 1994
2023
Q2 		– Sell
-11,395
Closed -$88.8K – 2449
2023
Q1 		$88.8K Buy
11,395
+1,021
+10% +$7.1K ﹤0.01% 2312
2022
Q4 		$78.9K Buy
+10,374
New +$86.4K ﹤0.01% 2330

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Principal Financial Group's GLUE Position: Q2 2026 in Review

Principal Financial Group increased its Monte Rosa Therapeutics (GLUE) stake by 16% in Q2 2026, buying an estimated $125K and bringing the position to 49,001 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1921.

Principal Financial Group first reported a position in GLUE in Q4 2022 and has held it in 4 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Principal Financial Group held 49,001 shares of Monte Rosa Therapeutics worth $1.19M as of Q2 2026.
  • Principal Financial Group bought 6,610 Monte Rosa Therapeutics shares in Q2 2026, an estimated $125K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1921 holding.
  • Principal Financial Group first reported a position in Monte Rosa Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.